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Abstract
Objectives—This is an open-pilot study to evaluate the feasibility, acceptability and efficacy of 
a pain-specific version of an established mind–body medicine program, the Relaxation Response 
[RR] Resiliency Program [R3P], in patients with chronic temporomandibular disorder [TMD].
Methods—Male and female with at least a six-month history of pain involving the masticatory 
muscles were sought in the Orofacial Pain Centers of the Massachusetts General Hospital [MGH] 
or through an advertisement sent to MGH employees from 2008 to 2010. Eligible participants 
underwent the R3P intervention [eight group sessions] after standard medical management. Pre- 
and post-group patients underwent objective measures of impairment [vertical and lateral range of 
motion with and without pain, temporomandibular joint and muscle pain palpation, and algometer 
measures] and completed psychosocial measures [Symptom Severity Index, Perceived Stress 
Scale, the Symptom Checklist-90-Revised and Short Form 36 Health Survey].
Results—Twenty-four subjects [16 females, 90% from MGH Orofacial Pain Centers,10% from 
among MGH employees], mean age 38 years, met eligibility criteria and participated in the study. 
The intervention was highly feasible and accepted by patients, as evidenced by a 92% rate of 
completion. Paired t-test analyses revealed improvement on self-reported pain measures: pain 
intensity [p<0.02], pain frequency [p<0.002], pain duration [p<0.027], pain tolerability [p<0.009] 
and on several objective tests.
Conclusions—The pain specific R3P is efficacious in reducing objective and subjective 
symptoms in patients with chronic refractory TMD. The comprehensive intervention, which 
combines educational information about pain with RR, cognitive behavioral and resiliency-
enhancement skills, is accepted by patients and may be more efficacious than other treatments 
with fewer elements.
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Introduction
Temporomandibular disorders [TMDs] are a heterogeneous collection of syndromes 
characterized by orofacial pain, masticatory dysfunction or both. The high cost of treating 
TMD is directly related to the unresponsiveness of chronic TMD to traditional medical/
dental approaches (1). Friction recommends a team approach [dentist, physical therapist and 
behavioral therapist] for the management of the masticatory muscle pain component of 
TMD symptoms (2).
Chronic TMD has received increasing attention from behavioral scientists. With the 
realization that psychosocial [e.g. stress, depression and anxiety] and physical factors may 
interact in the etiology and/or maintenance of TMD, a number of biobehavioral treatment 
modalities have been used effectively with these patients, including biofeedback (3,4), 
progressive muscle relaxation (5–7) and cognitive behavioral therapy [CBT] (8,9).
A recent series of studies evaluating the relative efficacy of four methods for treating 
chronic TMD [nonsurgical medical treatment alone, relaxation-biofeedback treatment, 
cognitive behavioral skills treatment [CBST], and combined relaxation-bio-feedback and 
CBST] showed a significant decrease in pain intensity and improvement in mood in the 
three biobehavioral groups as compared to the standard medical treatment (10,11). In these 
studies, relaxation-biofeedback was found to be most efficacious short term, while the 
combined treatment was found to be most efficacious at a one-year follow-up. Another 
study (12) compared the effects of combined education and medication, combined education 
and physical therapy and combined education and masseter muscle biofeedback training on 
symptom reduction in TMD patients and found that although all three groups showed 
reduction in symptoms, the combined education-medication group showed the most rapid 
improvements in pain intensity and jaw function (12). These studies were concordant with 
prior research suggesting that a combination of medical, relaxation, education and CBT 
components may be the most efficacious for short- and long-term treatment improvement in 
patients with TMD (3,5,13).
For over 25 years, the Massachusetts General Hospital [MGH] has been offering the 
Relaxation Response [RR] Resiliency Program [R3P, formerly called the Medical Symptom 
Reduction Program], a comprehensive and efficacious mind–body medicine approach to 
decreasing distress from chronic medical symptoms such as multiple sclerosis, 
gastrointestinal disorders, skin pathologies, chronic pain, anxiety, depression and 
autoimmune disorders (14). The program's core component is the elicitation of the RR, 
defined as a series of coordinated physiologic changes occurring when a person engages in a 
repetitive mental or physical action and passively acknowledges and then disregards 
[without judgment] distracting thoughts. These changes include decreases in oxygen 
consumption, heart rate, respiratory rate and blood pressure, along with a sense of quiet 
acceptance and peace. The changes are opposite to those that occur during the stress 
response. Living with chronic pain represents a huge stressor; learning to elicit the RR, 
paired with educational and simple cognitive behavioral skills, can help patients decrease 
pain symptoms and improve quality of life.
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In an open pilot study, we set out to test the feasibility, acceptability and efficacy of a 
modified R3P in reducing TMD-specific psychosocial and objective measures. The modified 
R3P contains elements found to be efficacious in previous interventions with TMD patients, 
including educational information, relaxation training and CBT skills. We hypothesized that 
the intervention would be feasible and accepted by patients, as evidenced by a high rate of 
program completion. We also hypothesized that there would be a significant improvement in 
psychosocial and objective TMD-specific symptoms upon intervention completion.
Materials and Methods
Participants
TMD patients were to be recruited from the Orofacial Pain Clinic at MGH and through an 
advertisement sent to MGH employees. The MGH Human Research Committee approved 
the study's procedures, and all patients underwent informed written consent procedures. 
Participants were identified by code and not by name or initials.
To be eligible, patients had to receive a primary myofascial pain syndrome [MPS, involving 
muscles of mastication] TMD diagnosis based on published Research Diagnostic Criteria 
[RDC] (15). All TMD diagnostics were conducted by a senior dentist with formal training in 
RDC procedures and reliability calibration. Additional eligibility criteria for TMD patients 
included minimal symptom duration greater than six months and a commitment to 
participate in the R3P [eight weeks]. We excluded patients who self-reported a primary pain 
condition other than TMD, a history of substance abuse or significant psychopathology, i.e. 
untreated, unresponsive or uncontrolled mental health disorders such as anxiety disorders, 
bipolar disorder, psychotic disorders or major depressive disorder.
All participants were to complete a four-week standard nonsurgical protocol. Upon 
completion of the standard treatment, patients were to undergo eight weeks of the R3P. 
Before and after the R3P, patients completed the following self-report psychosocial 
measures: Modified Symptom Severity Index [SSI] (16), Perceived Stress Scale [PSS] (17), 
Short Form-36 Health Survey [SF-36] (18) and Symptom Checklist-90-Revised [SCL-90-R] 
(19). Patients were also to participate in the following objective assessments, performed by a 
senior trained dentist: (1) vertical and lateral range of motion [ROM], with and without pain, 
(2) temporomandibular joint [TMJ] and muscle pain palpation, and (3) algometer measures.
Measures and instruments
Symptom checklist-90-revised—The SCL-90-R was used to assess psychological 
symptoms pre- and post-R3P (19,20). The SCL-90-R is a 90-item self-report symptom 
inventory; each item is rated on a five-point scale of distress, ranging from “not at all” [0] to 
“extremely” [5]. The 90 items are scored and interpreted in terms of nine primary 
dimensions and one global severity index. The nine dimensions are somatization, obsessive-
compulsiveness, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, 
paranoid ideations and psychoticism.
Modified SSI—The SSI was used to assess severity of pain symptoms pre- and post-R3P 
(16). This SSI is a five-item self-report instrument assessing pain frequency, duration, 
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intensity, unpleasantness and difficulty to endure. Potential responses for pain intensity, 
unpleasantness and difficulty to endure range from “zero” on the far left to “worst 
imaginable” on the far right. Responses for pain frequency and duration range from “never” 
on the far left to “constant” on the far right. Within the pain frequency and duration scales, 
descriptors are periodically posted between the extremes to spread the responses over the 
full scale. Frequency is defined as the number of episodes of pain that occurred during the 
past month. Duration is defined as the typical length of time each episode of pain was 
present during the same time frame, during the past month.
Short form 36 health survey—The SF-36 (16) is a patient-rated measure of quality of 
life. Eight subscales measure physical functioning, role-physical [limitations in daily 
activities caused by physical health], body pain, general health, role-emotional [limitations 
in daily activities due to emotional problems], vitality, social functioning and mental health. 
A number of studies have proven the SF-36 to be a reliable and valid measure of quality of 
life in populations with general medical illness, as well as those with chronic health 
problems such as heart disease, lung disease, diabetes, hypertension and major depression 
(21–23).
PSS, short form—The PSS (17) is a four-item scale designed to measure the degree to 
which situations in one's life over the past month are appraised or considered as stressful. 
Items were designed to detect how unpredictable, uncontrollable and overloaded 
respondents find their lives. Patients answer the four questions on a five-point Likert scale 
from “never” [0] to “very often” [4]. A total score is computed by summing up the items 
after two are reverse-scored.
Vertical and lateral ROM—The ROMs, both with and without pain, were measured in 
millimeters.
Pain palpation—Pain palpitation was performed by the dentist, and the pain was rated by 
the patients as mild, moderate or severe. In addition to the TMJ, the masticatory muscles 
[right and left middle temporalis, right and left masseter origin, right and left masseter body, 
and right and left masseter insertion] and neck muscles [right and left inferior 
sternocleidomastoid [SCM], right and left splenius capitis and right and left trapezius 
insertion] were also palpated and rated in terms of pain.
Algometer measures—Algometer measures for pain sensitivity with pressure were 
performed on the right and left temple and the right and left masseter. The algometer was 
placed over the subject's sensitive area [trigger point] in the temple and masseter areas. The 
subject was asked to raise their hand when first feeling pain while the examiner gradually 
increased pressure from the algometer. This process was repeated three times for each 
trigger point over a period of five minutes. The average of these three measurements was 
reported as the patient's PPT for that area.
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Treatments
Standard nonsurgical treatment—Standard therapy consisted of educational 
information about the nature of myofascial pain and its causes. Treatments included anti-
inflammatory and muscle relaxant medications to manage acute symptoms, appliance 
therapy to control parafunctional forces and stabilize occlusion, and simple jaw stretching 
exercises to reduce muscle tension and increase jaw ROM. The appliances were made from 
thermoplastic material and adjusted at delivery to have mutually protected occlusion in the 
subject's habitual jaw position. They were fitted to the arch [maxillary or mandibular] that 
would best stabilize the subject's occlusion and covered all the teeth on that arch. The 
subjects were instructed to wear the appliances at night.
RR resiliency program—The R3P is a comprehensive outpatient program based on the 
principles of mind–body medicine. The program consists of eight weekly group therapy 
sessions [6–10 participants per group], 1.5 hours in length. The program is designed to 
buffer the effects of stress and increase resiliency by teaching coping strategies. The 
foundation of the program is the elicitation of the RR, a physiological state that is the 
opposite of the stress [fight or flight] response. Patients are taught to elicit the RR in each 
session via a series of methods including imagery, mindfulness, contemplation, yoga and 
single-pointed focus meditation. The curriculum incorporates educational information about 
mind–body interactions and training to develop mind–body awareness. Patients also learn 
simple cognitive behavioral principles, including how to identify negative automatic 
thoughts and restructure them into more adaptive, positive thoughts. Other skills include 
activity scheduling, pacing, sleep hygiene and healthy eating strategies. The R3P was 
modified for this group to address the medical symptom of pain. To ensure the practice of 
skills at home, patients were given weekly homework assignments, which were reviewed at 
the beginning of each session. The last session was focused on reviewing all skills learned 
and discussing relapse prevention.
Statistical analyses—All data were analyzed with SPSS [Statistical Package for the 
Social Sciences; Chicago, IL] v.16.0. We used t-tests [for continuous variables] and chi-
squared tests [for categorical variables] to compare completers and noncompleters, and used 
frequencies and means to describe demographic and primary study variables. We used 
paired-sample tests to compare pre- and post-test means on continuous main study measures 
and objective measures of functioning, and Fisher's exact test to assess differences in 
frequencies of cases for categorical variables. We calculated effect sizes for the significant 
[p<0.05] and close to significant [p<0.1] pre- and post-mean differences, using Cohen's 
formula (24).
Results
Patient characteristics
Twenty-six [N = 26] patients with TMD including myofascial pain participated in the study. 
Ninety percent were recruited from the MGH Orofacial clinics and 10% came from the 
announcement to MGH employees. Among them, 24 patients [N = 24] completed the 
intervention [at least six of the eight group sessions] and provided post-test data. Dropouts 
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failed to show up for treatment sessions and were lost to follow-up. There were no 
differences in demographic or pretest variables between patients who completed the 
intervention and those who dropped out [p>0.05]. The average age of the patients was 38 
[standard deviation = 14.82, range 24–72]. The majority of participants were white [N = 22] 
and working full time [N = 14]; 16 were women, 9 were married and 11 had graduate school 
education. There were no significant differences by demographic variables in any of the 
study measures [p>0.05]. Table 1 presents demographic variables.
Feasibility of intervention
Fifty-seven patients met study criteria and were eligible to participate. Among them, 26 
committed to undergoing the eight-week R3P program at the specified available times and 
were enrolled [46%]. Of those enrolled, 24 [92%] completed at least six sessions and 
provided post-test data.
Intervention outcome
Paired-samples t-tests comparing pre- and post-test means on main study measures revealed 
significant or close to significant improvements on continuous self-report and objective 
measures of functioning [Table 2]. As depicted, there was a significant increase in SF-36 
mental health functioning, physical health dimension and overall health functioning and a 
trend toward increase in vitality [p<0.1]. There was also a decrease in SSI frequency, 
duration, intensity, unpleasantness and ability to endure symptoms [all p<0.05]. With regard 
to the objective measures, we found a significant increase in ROM with and without pain, 
and significant decrease in pain with palpation of right and left insertion masseter, right and 
left inferior SCM, right splenius capitis and right insertion trapezius [p<0.05]. There was 
also a significant increase in pain-pressure threshold in algometer measurements of the right 
and left temporalis and right and left masseter [p<0.05]. There was also a trend toward a 
decrease in pain from palpation of the right medial tempor-alis, right and left origin 
masseter, and right body masseter [p<0.1], SCM, splenius capitis and tra-pezius muscles 
[p<0.1]. All other measurements were not significant [p<0.1].
Discussion
This uncontrolled pilot study examines the response of a cohort of subjects who exhibit 
symptoms of a TMD. TMDs are multifaceted diseases with physical and psychosocial 
elements requiring a comprehensive treatment to address all aspects of the disorders. TMD 
is not a specific diagnosis, but represents a collection of problems with similar symptoms. 
To successfully manage a patient with TMD, one must identify the specific diagnoses that 
are contributing to their symptoms and treat each individually. A positive response to such 
individual treatments can collectively improve the patient's overall function and decrease the 
impact that jaw dysfunction [“TMD”] has for the patient. Before the study's “relaxation 
response” intervention, the subjects were given a “standard” therapy consisting of exercise 
therapy to improve pain-free jaw ROM and appliance therapy to control night-time 
parafunctional forces and daytime clenching if indicated. The appliances used were 
thermoplastic appliances all fabricated by the same lab adjusted to a jaw relation 
corresponding in the subject's habitual occlusion [maximum intercuspal position].
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The study looks at subjects exhibiting the specific diagnosis of MPS involving one or more 
muscles of mastication and their response to the behavioral intervention of the “relaxation 
response”. The intervention does not address the etiology of the subject's disease process; 
rather, it is aimed at helping patients adjust to a chronic condition.
This study's purpose is to examine the response of a group of subjects with chronic MPS of 
six months duration non-responsive to traditional non-operative therapy composed of jaw 
exercises, anti-inflammatory and mild analgesic medications, and appliance therapy to a 
standard program of relaxation-response treatment. The goal of this therapy is to “decrease 
pain symptoms and improve quality of life”, i.e. manage the illness associated with myo-
fascial pain. But as the etiology of myofascial pain can involve psychosocial factors as well 
as biomed-ical ones, the disease process for myofascial pain can also be affected by this R3P 
intervention. An example would be a subject whose muscle pain is related to a heightened 
autonomic nervous system response related to a past history of being subjected to physical 
abuse. Decreasing a heightened automatic nervous system response to stress via a R3P 
intervention would affect the actual disease affecting pain processing in such a subject. In 
general, one expects the benefit from a R3P intervention, rather than targeting the disease 
process affecting the patient, to enhance the subject's coping skills for management of the 
impact of their TMD symptoms.
In a sample of patients with TMD of the MPS type, we found that the pain-specific R3P 
intervention combining educational, RR and CBT elements is efficacious and accepted by 
patients. We also found significant improvements in pain-specific measures such as 
frequency, intensity, duration, unpleasantness and ability to endure symptoms, as well as 
psychological measures such as reports of mental health, physical health, total health 
functioning and a trend for vitality. Furthermore, we found improvement in several objective 
functioning measures including TMD-specific ROM and muscle functioning.
The findings of this study are consistent with previous reports (10,11) and underscore the 
benefits of incorporating the biopsychosocial perspective of pain in order to 
comprehensively deal with both physical and psychosocial concomitants of chronic pain 
conditions such as TMD. Given the high cost of treatment for TMD, its relative 
unresponsiveness to purely medical management approaches, and the established evidence 
that as the duration of pain increases, patients become more and more refractory and 
distressed, it is of utmost importance to identify patients at risk within the acute stage in 
order to prevent the development of chronicity and treatment difficulties. TMD may be best 
treated with multidisciplinary approaches, which include standard medical/dental treatment, 
as well as comprehensive psychosocial treatments such as R3P.
This study should be viewed in light of several limitations. First, patients were recruited 
from the MGH Orofacial Pain Clinic, a tertiary care facility, which serves patients with 
more severe, refractory TMD. Typically, such patients have undergone multiple medical/
dental treatments for their conditions with limited improvement. As such, our results are not 
fully generalizable. Although we believe that treatment effects would be higher with patients 
with less severe TMD, this is an open pilot study without a control group, which limits our 
internal validity. However, consistent with recommendations for design and testing of 
Vranceanu et al. Page 7
J Musculoskelet Pain. Author manuscript; available in PMC 2015 November 11.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
interventions (25), open pilot studies should precede larger randomized controlled 
interventions. We are in the process of conducting a randomized controlled trial testing the 
R3P versus a control intervention in TMD patients, as well as developing a reliable 
screening program to identify patients at risk for developing chronic refractory TMD. It is 
important to note, however, that although the small sample size limits our power, effect 
sizes, which are not affected by sample size, clearly show medium to large improvements in 
most subjective and objective measures.
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Table 1
Patient demographic and descriptive statistics for completers [N = 24].
Variable M [SD]/N [frequency]
Age 38.41 [14.82]
Gender
 Male 8 [33.3%]
 Female 16 [66.7%]
Race
 White 22 [91.7%]
 Asian 1 [4.2%]
 Others 1 [4.2%]
Marital
 Married 9 [37.5%]
 Widowed 1 [4.2%]
 Separated/divorced 1[4.2%]
 Never married and living alone 8[30.8%]
 Never married and living with partner 5 [23.2%]
Highest education
 Some college 5 [20.8%]
 College graduate 8 [33.3%]
 Graduate school 11 [45.8%]
Work status
 Full time 14 [58.3%]
 Part time 3 [12.5%]
 Homemaker 1 [4.2%]
 Unemployed 1 [4.2%]
 Others 5 [20.8%]
Income
 <$ 10 000 4 [18.2%]
 $ 10001–20 000 1 [4.5%]
 $ 20001–30 000 3 [13.6%]
 $ 30001–40 000 1 [4.5%]
 $ 40001–50 000 2 [9.1%]
 $ 60001–75 000 4 [18.2%]
 >$ 75 001 2 [9.1%]
 Refused 7 [30.4%]
M = mean; SD = standard deviation; N = number.
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